Daniel Sepúlveda-Crespo

Dr. Daniel Sepúlveda-Crespo

Instituto de Salud Carlos III, Madrid, Spain
orcid
Miguel Servet postdoctoral researcher

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
Daniel Sepúlveda-CrespoDaniel Sepúlveda-Crespo
Daniel Sepúlveda-Crespo
RGRafael Gómez
Rafael Gómez
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
JJJosé Luis Jiménez
José Luis Jiménez
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández


1 August 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
Daniel Sepúlveda-CrespoDaniel Sepúlveda-Crespo
Daniel Sepúlveda-Crespo
MSMaría Jesús Serramía
María Jesús Serramía
ATAndrew M. Tager
Andrew M. Tager
VVVladimir Vrbanac
Vladimir Vrbanac
RGRafael Gómez
Rafael Gómez
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández

31 March 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
María Álvarez BardónMaría Álvarez Bardón
María Álvarez Bardón
YPYolanda Pérez-Pertejo
Yolanda Pérez-Pertejo
COCésar Ordóñez
César Ordóñez
Daniel Sepúlveda-CrespoDaniel Sepúlveda-Crespo
Daniel Sepúlveda-Crespo
NCNestor Carballeira
Nestor Carballeira
RFRafael Balaña Fouce
Rafael Balaña Fouce
Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin.

1 April 2014 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
Daniel Sepúlveda-CrespoDaniel Sepúlveda-Crespo
Daniel Sepúlveda-Crespo
RLRaquel Lorente
Raquel Lorente
MLManuel Leal
Manuel Leal
RGRafael Gómez
Rafael Gómez
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández

13 March 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
Daniel Sepúlveda-CrespoDaniel Sepúlveda-Crespo
Daniel Sepúlveda-Crespo
RRRosa Reguera
Rosa Reguera
FRFrancisco Rojo‐Vázquez
Francisco Rojo‐Vázquez
RFRafael Balaña Fouce
Rafael Balaña Fouce
Maria Martinez-ValladaresMaria Martinez-Valladares
Maria Martinez-Valladares